Downloads: 2
Original Research | Dermatology | Volume 15 Issue 6, June 2026 | Pages: 1372 - 1377 | India
Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts - At a Tertiary Care Center in Central Karnataka
Abstract: Background: Cutaneous warts are common benign epidermal proliferations caused by human papillomavirus (HPV) infection. Although several treatment modalities are available, none is universally effective and recurrence remains a challenge. Intralesional Vitamin D3 has emerged as a promising immunotherapeutic option owing to its immunomodulatory properties and favorable safety profile. Objectives: To evaluate the efficacy and safety of intralesional Vitamin D3 in the treatment of cutaneous warts and to assess recurrence during follow-up. Methods: A prospective interventional study was conducted on 25 patients with cutaneous warts who fulfilled the inclusion and exclusion criteria. Intralesional Vitamin D3 was administered at two-week intervals until complete clearance or for a maximum of four sessions initially, with additional sessions provided when required. Clinical response was assessed at each visit and categorized as complete clearance, partial response, or poor/no response. Adverse effects and recurrence were recorded during a 6-month follow-up period. Results: The mean age of the study participants was 27.6 ? 9.4 years, with the majority belonging to the 21?30 years age group (44%). Males constituted 56% of the study population. Common warts were the most frequent clinical subtype (52%), followed by plantar (28%), periungual (12%), and flat warts (8%). Complete clearance was achieved in 18 patients (76%), while 5 patients (16%) showed a partial response and 2 patients (8%) demonstrated poor or no response. Most patients achieved clearance within 2?3 treatment sessions, with a mean of 3.1 ? 1.1 sessions required for complete resolution. Common warts showed the highest complete response rate (84.6%). Pain during injection was the most common adverse effect (88%), followed by swelling (76%) and erythema (72%). One patient (4%) developed keloid. No serious systemic adverse effects were observed. During the 6-month follow-up period, recurrence was noted in one patient (4%). Conclusion: Intralesional Vitamin D3 is an effective, safe, and well-tolerated therapeutic modality for cutaneous warts, producing high clearance rates with minimal adverse effects and low recurrence. It may serve as a useful alternative treatment option for patients with cutaneous warts.
Keywords: Cutaneous warts, Intralesional Vitamin D3, Immunotherapy, Human papillomavirus, Wart clearance, Recurrence
How to Cite?: Dr. K.S. Anisha Kabeer, Dr. Mangala H.C., Dr. Sugareddy, "Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts - At a Tertiary Care Center in Central Karnataka", Volume 15 Issue 6, June 2026, International Journal of Science and Research (IJSR), Pages: 1372-1377, https://www.ijsr.net/getabstract.php?paperid=SR26626011000, DOI: https://dx.doi.org/10.21275/SR26626011000